Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added May 08, 2022

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer progression and delaying PSA progression compared to AA for the treatment of patients with mCRPC.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: International Journal of Colorectal Disease | Added Apr 14, 2022

Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.

This study evaluated the risk of developing secondary rectal cancer after radiotherapy (RT) in patients with prostate cancer. The data showed that RT significantly increased the risk of developing secondary rectal cancer in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Jan 30, 2022

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jan 09, 2022

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness.

icon
prostate cancer | Research | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Nov 16, 2021

Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery

This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Nov 14, 2021

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical, functional, and oncological outcomes compared to LRP in these patients.

icon
prostate cancer | Research | 10 pages | source: The Lancet. Oncology | Added Nov 07, 2021

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: European Urology | Added Oct 24, 2021

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to RRP over the long term.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: European Urology | Added Oct 16, 2021

Reviewing focal therapies for patients with localized prostate cancer.

This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness. 

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Targeted oncology | Added Oct 11, 2021

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

View

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?